written on 03.04.2014
Tags:
,

Sanofi Japan sees growth for new products but generics bite

TAGS: ,

However, generic competition hit Allegra (fexofenadine; -18% to JPY47.1bn) and Myslee (zolpidem; -14% to JPY32bn).

Latest Report